Nebula Research & Development’s Syndax Pharmaceuticals SNDX Stock Holding History

Nebula Research & Development’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-27,231	Closed	-$255K	–	760
2025 Q2	$255K	Sell	27,231 -45,327	-62%	-$499K	0.02%	831
2025 Q1	$891K	Sell	72,558 -4,356	-6%	-$61.4K	0.08%	410
2024 Q4	$1.02M	Buy	76,914 +58,844	+326%	+$1.01M	0.12%	292
2024 Q3	$348K	Buy	+18,070	New	+$373K	0.04%	668

Other funds holding SNDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Nebula Research & Development's SNDX Position: Q3 2025 in Review

Nebula Research & Development sold out of Syndax Pharmaceuticals (SNDX) in Q3 2025, closing a stake of 27,231 shares — an estimated $255K sold.

Nebula Research & Development first reported a position in SNDX in Q3 2024 and held it in 4 quarters. The position peaked at $1.02M in Q4 2024. 227 funds tracked by Wall St. Rank hold SNDX as of Q3 2025.

Nebula Research & Development reported no remaining Syndax Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Nebula Research & Development sold 27,231 Syndax Pharmaceuticals shares in Q3 2025, an estimated $255K.
Nebula Research & Development first reported a position in Syndax Pharmaceuticals in Q3 2024 and held it in 4 quarters.
Nebula Research & Development's Syndax Pharmaceuticals position peaked at $1.02M in Q4 2024.
227 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.